Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: The Open Table Clear all
Terminated Phase 2 Interventional Results available

Riluzole to Treat Depression in Bipolar Disorder

NCT00054704
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional Results available

A Study of Overcoming Social Determinants of Health

NCT05773313
View directory record Official record
Conditions
Social Determinants of Health (SDOH)
Interventions
The Open Table
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

NCT06384417
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer, Head and Neck Cancer, Melanoma
Interventions
Hello for Cancer game, Table Topics game
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glottic View in Infants With a Shoulder Roll

NCT03424070
View directory record Official record
Conditions
Intubation;Difficult
Interventions
Shoulder Roll, No shoulder roll (placebo)
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
1 Day to 1 Year
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 25, 2026, 12:33 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Y-4 tablet, Pregabalin capsule, Riluzole tablet
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

NCT03510208
View directory record Official record
Conditions
Malignant Brain Neoplasm, Malignant Glioma
Interventions
Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800, POINPOINT-IR9000
Procedure · Biological · Drug + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

NCT04085887
View directory record Official record
Conditions
Brain Tumor
Interventions
Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera, PDE-NEO-II
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

NCT01504841
View directory record Official record
Conditions
HIV Infections
Interventions
Etravirine (ETR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 25, 2026, 12:33 AM EDT
Terminated Phase 3 Interventional Results available

Vortioxetine to Prevent Return of Symptoms in Children With Depression

NCT05014919
View directory record Official record
Conditions
Depression
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Atlanta, Georgia • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Entrainment Between Clinician and Patient During Palpation

NCT03579238
View directory record Official record
Conditions
Doctor Patient Relation
Interventions
CV4, touching
Procedure
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional

Improving Pediatric Obesity Practice Using Prompts

NCT03648242
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Interruptive Clinical Decision Support
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

NCT04577014
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
Interventions
Retifanlimab, Gemcitabine, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 2 Interventional Results available

Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.

NCT00550147
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Oros Methylphenidate, quetiapine
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 25, 2026, 12:33 AM EDT
Terminated Phase 4 Interventional Results available

Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills

NCT03588806
View directory record Official record
Conditions
Chronic Pain, Opioid Use, Deglutition
Interventions
Xtampza ER (oxycodone)
Drug
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing a Clinical Outcome Assessment for Opioid Craving

NCT05109429
View directory record Official record
Conditions
Opioid Craving, Opioid Use Disorder, Measure Development
Interventions
Neutral Cue-induced Craving, Visual Opioid Cue-induced Craving, Visual and Tactile Opioid Cue-induced Craving
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 2 Interventional

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Bakersfield, California • Palm Springs, California • West Hollywood, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

NCT00485264
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
29
States / cities
Alhambra, California • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Recruiting No phase listed Observational

Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

NCT02897908
View directory record Official record
Conditions
Disease of Liver and Bile Duct
Interventions
vibration controlled transient elastography (VCTE)
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

NCT01697930
View directory record Official record
Conditions
Solid Malignancy, Lymphoma
Interventions
[18F] 4-L-Fluoroglutamine (2S,4R)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

NCT01359319
View directory record Official record
Conditions
Hereditary Inclusion Body Myopathy (HIBM)
Interventions
Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Costa Mesa, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 25, 2026, 12:33 AM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 25, 2026, 12:33 AM EDT